Penicillin and Streptomycin Market Valued at $3.3 billion in 2025, Set to Grow at a 7.0% CAGR

Penicillin and streptomycin market was valued at $3.3 billion in 2025 and is projected to reach $6.5 billion by 2035, growing at a CAGR of 7.0% during the forecast Period (2026-2035). Regulatory approvals for locally manufactured penicillin derivatives have enhanced production capacity, ensuring a steady supply of antibiotics and reducing shortages, thereby stimulating growth in the penicillin and streptomycin market. For instance, in December 2025, the US FDA approved a US-manufactured version of amoxicillin–clavulanate (Augmentin XR) under a priority review program aimed at strengthening domestic antibiotic supply chains. This approval is significant for the penicillin class, as amoxicillin is a key penicillin derivative, and the initiative focuses on reducing antibiotic shortages, improving local manufacturing capacity, and ensuring the consistent availability of essential antibiotics. The approval was completed in approximately two months, highlighting the FDA’s increasing emphasis on supply chain resilience and the accessibility of critical antibacterial drugs, which indirectly supports the broader penicillin and streptomycin market.

Browse the full report description of “Penicillin and Streptomycin Market Size, Share & Trends Analysis by Product Type (Penicillin, and Streptomycin), By Manufacturing Process (Natural, Semi-synthetic, and Synthetic), By Route of Administration (Oral, Intramuscular, and Intravenous), By Application (Therapeutic Use, Laboratory / Cell Culture Use, Veterinary Use, and Others) and By End-User (Hospitals, Clinics, Retail Pharmacies, Online Pharmacies, Research & Academic Institutes, Veterinary Facilities, and Others), Forecast Period (2026-2035)” at https://www.omrglobal.com/industry-reports/penicillin-and-streptomycin-market

Regulatory Updates Strengthening Antibiotic Effectiveness and Clinical Guidance

• In February 2026, the US FDA recognized the latest Clinical and Laboratory Standards Institute (CLSI) antimicrobial susceptibility testing standards (M100, 36th edition), which guide how antibiotics, including penicillin-class drugs, are tested for effectiveness against bacteria. These updates help ensure accurate interpretation of bacterial resistance and support clinicians in selecting appropriate antibiotic therapies. While no new FDA approvals have been issued specifically for penicillin or streptomycin due to their mature generic status, such regulatory updates play a critical role in maintaining their clinical relevance, guiding usage, and addressing antimicrobial resistance challenges in modern healthcare settings.

Market Coverage

• The market number available for – 2025-2035
• Base year- 2025
• Forecast period- 2026-2035
• Segment Covered-
  • By Product Type
  • By Manufacturing Process
  • By Route of Administration
  • By Application
  • By End User
• Regions Covered-
  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World
• Competitive Landscape - Aurobindo Pharma Ltd., GlaxoSmithKline plc (GSK), Merck & Co., Inc., Pfizer Inc., Sandoz Group AG, among others

Key questions addressed by the report.

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• Who is the leader in the market?
• How are players addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Penicillin and Streptomycin Market Report Segment

By Product Type

• Penicillin
• Streptomycin

By Manufacturing Process

• Natural
• Semi-synthetic
• Synthetic

By Route of Administration

• Oral
• Intramuscular
• Intravenous

By Application

• Therapeutic Use
• Laboratory / Cell Culture Use
• Veterinary Use
• Others

By End-User

• Hospitals
• Clinics
• Retail Pharmacies
• Online Pharmacies
• Research & Academic Institutes
• Veterinary Facilities
• Others

Global Penicillin and Streptomycin Market Report Segment by Region

North America

• United States
• Canada

Europe

• UK
• Germany
• Italy
• Spain
• France
• Russia
• Rest of Europe

Asia-Pacific

• China
• India
• Japan
• South Korea
• Australia and New Zealand
• ASEAN Economies
• Rest of Asia-Pacific

Rest of the World

• Latin America
• Middle East & Africa

To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/penicillin-and-streptomycin-market